Tesnatilimab - CISMeF

Preferred Label : Tesnatilimab;

NCIt definition : A recombinant human immunoglobulin G4 (IgG4) monoclonal antibody against the immune activating receptor natural-killer group 2, member D receptor protein (NKG2D or KLRK1), with potential immunomodulating and anti-inflammatory activities. Upon administration, tesnatilimab targets and binds to NKG2D expressed on human natural killer (NK) and certain T-lymphocytes, and blocks the activation of NKG2D. This may inhibit both the cytotoxic activities of lymphocytes and the production of pro-inflammatory cytokines. NKG2D, a dimeric, type II transmembrane protein expressed on human NK and certain T-cells, and its ligands play important roles in some inflammatory and autoimmune conditions.;

UNII : 2B860WP9F0;

CAS number : 2242758-08-1;

Molecule name : JNJ 64304500; JNJ-64304500; IPH-2301; NN-8555; JNJ-4500;

NCI Metathesaurus CUI : CL1413035;

Details

Origin ID

C175864;

UMLS CUI

C5432260;

Currated CISMeF NLP mapping
- Tesnatilimab [SMS substance]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients